CAR-T-Zell-Therapie Logo
  • Aktuelles
  • Studien
  • Zentren
  • Patienteninfos
  • Fortbildung
  • Zulassungen
  • Fachbeiträge
  • Community
  • Login
Suche
zurück zur Zentren Übersicht
Salzburg

LKH Salzburg – Universitätsklinikum der PMU Universitätsklinik für Innere Medizin III

Müllner Hauptstraße 48
A-5020 Salzburg
Leitung: ao.Univ.-Prof. Dr. Alexander Egle

Studien

  • A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
  • A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
  • Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
  • A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Kontakt

OA Ao. Univ. Prof. Dr. Alexander Egle
a.egle@salk.at
+43 (0)5-7255-57700
Mag. Michaela Schachner
Studienbüro
m.schachner@salk.at
+43 (0)5 7255 57902
OA Assoc. Prof. Dr. Thomas Melchardt
t.melchardt@salk.at
+43 (0)5-7255-58840
OA Dr. Gudrun Russ
g.russ@salk.at
+43 (0)5-7255-57896
OA Dr. Michael Leisch
m.leisch@salk.at
+43 (0)5-7255-55891
Assoc. Prof. Dr. DI. Lisa Pleyer, MBA MSc
Stammzelllabor
l.pleyer@salk.at
+43 (0)5-7255-58249

Studien

  • A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
  • A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
  • Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
  • A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)
  • Aktuelles
  • Studien
  • Zentren
  • Patienteninfos
  • Fortbildung
  • Fachbeiträge
  • Zulassungen
  • Community
  • CARTakut
  • Aktuelles
  • Studien
  • Zentren
  • Patienteninfos
  • Fortbildung
  • Fachbeiträge
  • Zulassungen
  • Community
  • CARTakut
Ein Projekt von:
In Zusammenarbeit mit:
  • Impressum
  • Datenschutz
  • Cookie Einstellungen